erlotinib hydrochloride has been researched along with n-isopropylacrylamide in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (n-isopropylacrylamide) | Trials (n-isopropylacrylamide) | Recent Studies (post-2010) (n-isopropylacrylamide) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 589 | 1 | 345 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbasi, YF; Bera, H; Gajbhiye, V; Kesavan, S; Kumar, P; Ping, LL; Salve, R; Shaikh, SA | 1 |
1 other study(ies) available for erlotinib hydrochloride and n-isopropylacrylamide
| Article | Year |
|---|---|
Chemosensitivity assessments of curdlan-doped smart nanocomposites containing erlotinib HCl.
Topics: A549 Cells; Acrylamides; Adsorption; Bentonite; beta-Glucans; Cell Survival; Drug Liberation; Endocytosis; Erlotinib Hydrochloride; Humans; Hydrogen-Ion Concentration; Kinetics; Mucins; Nanocomposites; Particle Size; Spectroscopy, Fourier Transform Infrared; Staining and Labeling; Static Electricity; Temperature; Thermogravimetry; X-Ray Diffraction | 2021 |